bezafibrate has been researched along with Coronary Artery Disease in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (34.29) | 18.2507 |
| 2000's | 14 (40.00) | 29.6817 |
| 2010's | 9 (25.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldbourt, U; Lutski, M; Tanne, D; Weinstein, G | 1 |
| Brenner, R; Gerber, Y; Goldenberg, I; Hasin, T; Iakobishvili, Z; Klempfner, R; Kornowski, R; Shlomo, N | 1 |
| Behar, S; Benderly, M; Eisen, A; Goldbourt, U; Haim, M | 1 |
| Arbel, Y; Benzekry, S; Erez, A; Fisman, EZ; Goldenberg, I; Klempfner, R; Shlomo, N; Tenenbaum, A | 1 |
| Erez, A; Fisman, E; Goldenberg, I; Israel, A; Klempfner, R; Kopel, E; Sagit, BZ; Shlomo, N; Tenenbaum, A | 1 |
| Fisman, EZ; Goldenberg, I; Klempfner, R; Peled, Y; Shlomo, N; Tenenbaum, A; Tzur, B; Younis, A | 1 |
| Adler, Y; Behar, S; Boyko, V; Feinberg, MS; Fisman, EZ; Goldenberg, I; Motro, M; Schwammenthal, E; Shemesh, J; Tanne, D; Tenenbaum, A | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldberg, I; Inoue, T; Matas, Z; Node, K; Schwammenthal, E; Tenenbaum, A | 1 |
| Behar, S; Boyko, V; Brodov, Y; Chouraqui, P; Goldenberg, I | 1 |
| Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kugiyama, K; Mishina, H; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Watanabe, K; Watanabe, Y; Yano, T | 1 |
| Behar, S; Boyko, V; Brodov, Y; Chouraqui, P | 1 |
| DU, J; Hao, G; Huang, J; Liu, JH; Lü, Y; Wang, GZ; Zeng, XJ; Zhang, LK; Zhang, YC; Zhao, DH | 1 |
| Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Duriez, P; Fruchart, JC | 1 |
| Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Haim, M; Matas, Z; Motro, M; Tanne, D; Tenenbaum, A | 1 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Hidaka, H; Hongo, M; Ikeda, U; Kinoshita, O; Kumazaki, S; Mawatari, E; Takahashi, M; Tsutsui, H; Yazaki, Y | 1 |
| Charach, G; Grosskopf, I; Iaina, A; Judevices, R; Mor, R; Rubinstein, A; Weintraub, MS; Wollman, Y | 1 |
| de Faire, U; Ericsson, CG; Hamsten, A; Nilsson, J | 1 |
| Eliav, O; Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| Agmon, J; Behar, S; Caspi, A; Goldbourt, U; Graff, E; Kaplinsky, E; Kishon, Y; Mandelzweig, L; Reicher-Reiss, H; Weisbort, J | 1 |
| de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B | 3 |
| Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B | 1 |
| Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P | 1 |
| Kesäniemi, YA | 1 |
| Ericsson, CG | 1 |
| de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Karpe, F; Nilsson, J; Ruotolo, G; Svane, B; Tettamanti, C | 1 |
| Båvenholm, P; Brismar, K; de Faire, U; Eféndic, S; Ericsson, CG; Hamsten, A; Nilsson, J; Ruotolo, G | 1 |
| Brinton, EA; Krakoff, J; Vela, BS | 1 |
| Rubins, HB | 1 |
| Vita, JA; Winniford, M; Yeung, AC | 1 |
| Hirano, T; Kazumi, T; Yoshino, G | 1 |
| Bros, R; Domènech, P; Fiol, C; Meco, JF; Pintó, X; Pujol, R; Vila, R | 1 |
8 review(s) available for bezafibrate and Coronary Artery Disease
| Article | Year |
|---|---|
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Diet, Atherogenic; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Survival Rate; Treatment Outcome | 1996 |
Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
Topics: Bezafibrate; Coronary Angiography; Coronary Artery Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 1997 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Topics: Adult; Bezafibrate; Cholesterol; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Recurrence; Treatment Outcome; Triglycerides | 1998 |
The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides | 2000 |
Triglycerides and coronary heart disease: implications of recent clinical trials.
Topics: Aged; Bezafibrate; Controlled Clinical Trials as Topic; Coronary Artery Disease; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Prognosis; Treatment Outcome; Triglycerides | 2000 |
[BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
20 trial(s) available for bezafibrate and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiovascular Health and Cognitive Decline 2 Decades Later in Men with Preexisting Coronary Artery Disease.
Topics: Aged; Bezafibrate; Blood Glucose; Blood Pressure Determination; Cholesterol, LDL; Cognitive Dysfunction; Coronary Artery Disease; Health Behavior; Health Status Indicators; Humans; Hypolipidemic Agents; Israel; Male; Middle Aged; Risk Factors; Secondary Prevention | 2018 |
Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease.
Topics: Age Factors; Aged; Bezafibrate; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Female; Fibrinogen; Follow-Up Studies; Heart Failure; Humans; Hypolipidemic Agents; Incidence; Inflammation; Israel; Leukocyte Count; Male; Middle Aged; Risk Factors; Time Factors | 2014 |
Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
Topics: Aged; Bezafibrate; Biomarkers; Chi-Square Distribution; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Intention to Treat Analysis; Israel; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides | 2016 |
Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Topics: Aged; Bezafibrate; Biomarkers; Chi-Square Distribution; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Registries; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation | 2016 |
Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Triglycerides | 2010 |
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperuricemia; Hypolipidemic Agents; Incidence; Israel; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Triglycerides; Uric Acid | 2010 |
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation | 2005 |
Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
Topics: Adiponectin; Aged; Atorvastatin; Bezafibrate; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.
Topics: Aged; Aorta; Bezafibrate; Blood Flow Velocity; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Linear Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pulsatile Flow; Risk Factors; Treatment Outcome | 2008 |
Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis.
Topics: Aged; Bezafibrate; Cholesterol, HDL; Chylomicrons; Coronary Artery Disease; Coronary Disease; Diterpenes; Eating; Fasting; Humans; Hypolipidemic Agents; Hypolipoproteinemias; Lipoproteins; Male; Middle Aged; Retinyl Esters; Triglycerides; Vitamin A | 1995 |
Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Humans; Hypolipidemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Myocardial Infarction; Patient Compliance; Research Design; Risk Factors; Triglycerides | 1995 |
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Creatine Kinase; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Male; Middle Aged; Patient Compliance; Placebos; Safety; Triglycerides | 1995 |
Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
Topics: Aged; Algorithms; Bezafibrate; Cholesterol, HDL; Clinical Protocols; Coronary Artery Disease; Death, Sudden, Cardiac; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides | 1993 |
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Feasibility Studies; Fibrinogen; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Risk Factors; Time Factors; Triglycerides | 1996 |
Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Diet, Atherogenic; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Survival Rate; Treatment Outcome | 1996 |
Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Diet, Fat-Restricted; Disease Progression; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Risk Factors; Time Factors | 1997 |
Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Coronary Artery Disease; Coronary Disease; Glucose; Homeostasis; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha | 1998 |
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Topics: Adult; Bezafibrate; Cholesterol; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Recurrence; Treatment Outcome; Triglycerides | 1998 |
Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (B
Topics: Adult; Apolipoproteins; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Treatment Outcome | 1998 |
Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Topics: Adult; Bezafibrate; Biomarkers; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Lipoproteins; Male; Myocardial Infarction; Treatment Outcome | 2000 |
9 other study(ies) available for bezafibrate and Coronary Artery Disease
| Article | Year |
|---|---|
Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinogen; Humans; Hypolipidemic Agents; Israel; Lipids; Male; Middle Aged; Neoplasms; Registries; Risk Reduction Behavior; Triglycerides | 2019 |
Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.
Topics: Age Factors; Aged; Bezafibrate; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Registries; Renal Insufficiency; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2016 |
Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
Topics: Aged; Bezafibrate; Colonic Neoplasms; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Kaplan-Meier Estimate; Ligands; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic | 2008 |
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
Topics: Aged; Bezafibrate; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Randomized Controlled Trials as Topic; Severity of Illness Index | 2009 |
Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
Topics: Aged; Analysis of Variance; Bezafibrate; Biomarkers; C-Reactive Protein; Cohort Studies; Confidence Intervals; Coronary Artery Disease; Endpoint Determination; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid | 2009 |
Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells.
Topics: Animals; Apoptosis; Bezafibrate; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Fibroblast Growth Factors; Lipoproteins, LDL; Male; PPAR alpha; Rats; Rats, Wistar; RNA, Messenger | 2010 |
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Topics: Aged; Bezafibrate; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Humans; Male; Myocardial Infarction; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Simvastatin; Survival Rate; Treatment Outcome | 2001 |
Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate.
Topics: Aged; Bezafibrate; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Humans; Hypolipidemic Agents; Male; Middle Aged; Statistics, Nonparametric; Tangier Disease; Vasodilation | 2001 |